Medera’s merger is a rare example of a SPAC deal in biotech in 2024. After a number of high-profile announcements were made ...

The bacteria Chlamydia trachomatis is best known for infecting genitals, causing the sexually transmitted infection (STI) ...

When Johnson & Johnson moved to purchase the surgical robot developer Auris Health in 2019 for $3.4 billion in cash, like in ...

With the rollout of its new over-the-counter continuous glucose monitor, Abbott aims to help its customers speak the hidden ...

Eli Lilly has vaulted into an AI-enabled drug discovery deal, partnering with RNA specialist Genetic Leap in a pact worth up ...

Astellas Pharma has cut the ribbon on a new life sciences center in Massachusetts that will house 400 team members and an ...

Lykos CEO and founder Amy Emerson is stepping down, with chief operating officer Michael Mullette taking over the top spot on ...

Voyager is granting Novartis the license as part of the deal the companies entered into in March 2022. Novartis paid $54 ...

Just a few months after dosing the first patient in a phase 2 trial for newly diagnosed glioblastoma, IN8bio is hitting the brakes—and laying off half of its workforce.

Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment ...

Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers ...

Eli Lilly’s hunt for obesity targets has led it to the dark genome. | Eli Lilly’s hunt for obesity targets has led it to the ...